A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of TNP-2198 Capsules After Single Oral Dose in Healthy Participants

Study Overview
=================
Brief Summary
-----------------
This was a single-center, randomized, double-blind, placebo-controlled phase 1 study to evaluate the safety, tolerability, pharmacokinetics of single ascending dose and the food effect on the pharmacokinetics of TNP-2198 capsules after single dose oral administration in healthy subjects.

Official Title
-----------------
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose of TNP-2198 Capsules in Healthy Participants and the Effect of Food on the Pharmacokinetics of TNP-2198 Capsules in Healthy Participants

Conditions
-----------------
Helicobacter Pylori Infection

Intervention / Treatment
-----------------
* Drug: TNP-2198
* Drug: TNP-2198 Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Those signed the informed consent form and fully understood the study contents, process and possible adverse reactions before participation in the study; Those are able to complete the study according to the requirements of the study protocol; Those (including the partner) are willing to use effective contraceptives from the screening up to 6 months after the last dose of study drug; Male and female subjects aged 18 to 55 years (inclusive); Male subjects no less than 50 kg and female subjects no less than 45 kg. BMI (Body Mass Index= body weight (kg)/height^2 (m^2)): 18-28kg/m^2 (inclusive); Health status: no clinically significant history of heart, liver, kidney, digestive tract, nervous system, respiratory system diseases, mental disorders or metabolic abnormalities; Normal results or abnormal results without clinical significance in physical examinations and vital signs; Clinical laboratory test results are within normal limits or abnormal but without clinical significance as judged by the investigator. Exclusion Criteria: Average daily consumption of more than 5 cigarettes within 3 months before the study; History of hypersensitivity to study drug or its excipients, or allergic constitution (allergy to multiple drugs and food); History of drug and/or alcohol abuse (mean consumption of ≥ 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of liquor, or 100 mL of wine); Blood donation or massive blood loss (> 450 mL) within 3 months prior to screening; Using any drug that changes liver enzyme activity within 28 days prior to screening; Using any prescription drug, over-the-counter drug, any vitamin product, or herbal medicine within 14 days prior to screening; Taking special diet (including dragon fruit, mango, grapefruit, etc.) or strenuous exercise, or having other factors that affect drug absorption, distribution, metabolism, excretion, etc., within 2 weeks prior to screening; Significant changes in diet or exercise habits recently; Taking other study drugs or participating in other clinical studies within 3 months before taking the study drug; With difficulty in swallowing or history of any gastrointestinal diseases that affect drug absorption; With any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis or gastric and duodenal ulcers; Unable to tolerate standardized meal (two boiled eggs, one butter bacon toast, one box of fried potato chips, and one cup of whole milk) (only for subjects participating in the food effect study); With clinically significant ECG abnormalities; Female subjects who are lactating or have positive serum pregnancy result during the screening period, or have positive serum pregnancy result during the study; With symptoms or previous history of cardiovascular, digestive, respiratory, urinary, neurological, hematologic, immunological, endocrine system diseases, tumor, or psychiatric diseases; Clinically significant abnormalities in clinical laboratory tests, or other clinically significant findings (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immunological, psychiatric, or cardiovascular disease); Positive viral hepatitis (including hepatitis B and C), HIV antibody, treponema pallidum antibody; Acute illness or concomitant medication from the time of signing informed consent to the time of study medication; Intake of chocolate, any caffeine- or xanthine-containing food or drink within 48 hours prior to administration of study drug; Intake of any alcohol-containing products within 48 hours prior to administration of study drug; Positive urine drug screening or history of drug abuse or drug addiction within the past 5 years; Other conditions that, in the opinion of the investigator, make the patient participating in this study inappropriate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single Ascending Doses Cohort 1<br>TNP-2198 Capsules 50mg | Drug: TNP-2198<br>* Oral<br>* Other names: Rifasutenizol;|
| Experimental: Single Ascending Doses Cohort 2<br>TNP-2198 Capsules 100mg | Drug: TNP-2198<br>* Oral<br>* Other names: Rifasutenizol;|
| Experimental: Single Ascending Doses Cohort 3<br>TNP-2198 Capsules 200mg | Drug: TNP-2198<br>* Oral<br>* Other names: Rifasutenizol;|
| Experimental: Single Ascending Doses Cohort 4<br>TNP-2198 Capsules 400mg | Drug: TNP-2198<br>* Oral<br>* Other names: Rifasutenizol;|
| Experimental: Single Ascending Doses Cohort 5<br>TNP-2198 Capsules 600mg | Drug: TNP-2198<br>* Oral<br>* Other names: Rifasutenizol;|
| Experimental: Single Ascending Doses Cohort 6<br>TNP-2198 Capsules 800mg | Drug: TNP-2198<br>* Oral<br>* Other names: Rifasutenizol;|
| Experimental: Single Ascending Doses Cohort 7<br>TNP-2198 Capsules 1000mg | Drug: TNP-2198<br>* Oral<br>* Other names: Rifasutenizol;|
| Experimental: Food Effect Cohort 8<br>TNP-2198 Capsules 200mg | Drug: TNP-2198<br>* Oral<br>* Other names: Rifasutenizol;|
| Placebo Comparator: Placebo Cohort 9<br>Placebo | Drug: TNP-2198 Placebo<br>* The placebo for TNP-2198 active drug<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants With Adverse Events (AEs) | An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events. | Day 1 to Day 4 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) | Plasma concentrations of TNP-2198 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2198 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. | Hour 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 after administration. | 
| Area Under the Plasma Concentration Versus Time Curve from 0 to the Last Measurable Concentration (AUC0-t) | Plasma concentrations of TNP-2198 were measured by a specific and validated assay. Plasma PK parameters of TNP-2198 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. | Hour 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 after administration. | 
| Maximum Observed Plasma Concentration (Cmax) of TNP-2198 | Plasma concentrations of TNP-2198 were measured by a specific and validated assay at specified time points | Hour 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 after administration. |